Versant Venture Capital
SelectiveSan Francisco, CABiotechnology, Healthcare, PharmaceuticalsLast fund filed April 2024
6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Versant Venture Capital SPV I (SAB), L.P. | April 2024 | $5M | $5M | 2 |
| Versant Venture Capital IX, L.P. | October 2022 | $600M | $600M | 82 |
| Versant Venture Capital VIII, L.P. | November 2020 | $560M | $560M | 87 |
| Versant Venture Capital VII, L.P. | September 2018 | $600M | $600M | 74 |
| Versant Venture Capital VI, L.P. | November 2016 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
11 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Kirk NielsenNot on the current fund | Selective | Medical devices, Biotech & pharma, Digital health | 18 |
Classified sectors of Versant Venture Capital’s own portfolio companies, based on 78 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Versant Vantage | 39 | 858 Therapeutics, Aligos Therapeutics, Audentes Therapeutics, BIRD ROCK BIO, Bright Peak Therapeutics, Century Therapeutics, ChanRx, Chinook Therapeutics U.S., CRISPR Therapeutics AG, Euro Ventures 4, Firefly Bio, Graphite Bio, Inception 5, Inception IBD, Jengu Therapeutics, Jnana Therapeutics, Kanyos Bio, Launchpad Therapeutics, Lenz Therapeutics, Lycia Therapeutics, March Therapeutics, Mistral Therapeutics, Monte Rosa Therapeutics, Nexo Therapeutics, Northern Mosaic, Oyster Point Pharma, Pandion Therapeutics Holdco, Pandion Therapeutics, Pep2Tango Therapeutics, Quentis Therapeutics, RayzeBio, Santa Ana Bio, Tempest Therapeutics, Tentarix Biotherapeutics, Travus Therapeutics, Turnstone Biologics, VenatoRx Pharmaceuticals, Ventus Therapeutics U.S., Vividion Therapeutics |
| U.S Venture Partners | 4 | Inari Medical, Okami Medical, Sequent Medical, ViaLase |
| $400M |
| $400M |
| 57 |
| Versant Venture Capital V, L.P. | October 2013 | $300M | $296M | 86 |
| 3 |
| Alex Mayweg | Quiet | Biotech & pharma | 5 | 0 |
| Bradley Bolzon | Quiet | Biotech & pharma | 10 | 0 |
| Carlo RizzutoNot on the current fund | Quiet | Biotech & pharma | 10 | 0 |
| Clare Ozawa | Quiet | Biotech & pharma | 8 | 0 |
| Jerel Davis | Quiet | Biotech & pharma | 13 | 0 |
| Robin Praeger | Quiet | None listed | 0 | 0 |
| Ross JaffeNot on the current fund | Quiet | Medical devices, Digital health | 5 | 0 |
| Samuel ColellaNot on the current fund | Quiet | Biotech & pharma, Climate & energy, Manufacturing & industrials | 5 | 0 |
| Thomas Woiwode | Quiet | Biotech & pharma | 13 | 0 |
| William LinkNot on the current fund | Quiet | Medical devices, Biotech & pharma, Digital health | 16 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Versant Venture Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Stack Infrastructure | 3 | Inari Medical, Okami Medical, Sequent Medical |
| Vivo Capital | 3 | Aligos Therapeutics, Kanyos Bio, MINERVA SURGICAL |
| MPM BioVentures | 2 | Aligos Therapeutics, Firefly Bio |
| Polaris Partners | 2 | Jnana Therapeutics, Quentis Therapeutics |
| ARCH Venture Partners | 1 | Vividion Therapeutics |
| Caduceus Capital | 1 | Audentes Therapeutics |
| Camber Creek | 1 | Alleviant Medical |
| Lightstone Ventures | 1 | HOLAIRA |
| New Enterprise Associates | 1 | Ceterix Orthopaedics |
| Orbimed Asia Partners | 1 | Audentes Therapeutics |
| Orbimed New Horizons | 1 | Audentes Therapeutics |
| Orbimed Partners | 1 | Audentes Therapeutics |
| Pivotal bioVenture Partners | 1 | Ceterix Orthopaedics |
A shared board seat: a company where filings name a Versant Venture Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.